(Q34737866)

4 August 2017

1 reference

title

Parvoviruses and blood products (English)

1 reference

4 August 2017

Ruth Laub

1

1 reference

4 August 2017

Paul Strengers

series ordinal

2

1 reference

4 August 2017

publication date

1 June 2002

1 reference

4 August 2017

published in

Pathology and Biology

1 reference

4 August 2017

volume

50

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

339-348

1 reference

Human parvoviruses: implications for transfusion medicine

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Novel human erythrovirus associated with transient aplastic anemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Antineoplasic activity of parvoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Erythrocyte P antigen: cellular receptor for B19 parvovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Viral-associated haemophagocytosis and elevated serum TNF-alpha with parvovirus-B19-related pancytopenia in patients with hereditary spherocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Pathogenesis of human parvovirus B19 in rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19 infection in acute fulminant liver failure

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Neuralgic amyotrophy due to parvovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Parvovirus B19 infection associated with the production of anti-neutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibody (aCL).

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19 infection in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

A study of the role of parvovirus B19 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Experimental parvoviral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19 as a causative agent for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Sequence variability among different parvovirus B19 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19: relevance in internal medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

The presidential candidates and health care

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Parvovirus B19 diagnosis in pregnant women--quantification of IgG antibody levels (IU/ml) with reference to the international parvovirus B19 standard serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

The prevalence of antibody to human parvovirus B19 in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19).

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Blood donor screening for parvovirus B19.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Incidence of human parvovirus B19 DNA detection in blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Occurrence and clinical role of active parvovirus B19 infection in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Parvovirus B19 transmitted by bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Epitope Type-Specific IgG Responses to Capsid Proteins VP1 and VP2 of Human Parvovirus B19

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19.

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Prevalence of Antibodies against Parvovirus B19 in Norwegians with Congenital Coagulation Factor Defects Treated with Plasma Products from Small Donor Pools

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Prevalence of human parvovirus B19 DNA and IgG/IgM antibodies in Polish haemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Parvovirus B19 infection in patients with hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Possible transmission of parvovirus B19 from intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Grou

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Transmission of human parvovirus B19 by coagulation factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Parvovirus B19: implications for transfusion medicine. Summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood CD34+ cells

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

Investigation of porcine parvovirus among persons with hemophilia receiving Hyate:C porcine factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0369-8114%2802%2900303-6

7 January 2021

10.1016/S0369-8114(02)00303-6

Identifiers

DOI

1 reference

4 August 2017

1 reference